Rightongene released its 2026 interim report on August 27. Affected by intensifying competition in the in-vitro diagnostics industry and stricter regulation, the company's revenue and profit both declined, and net profit attributable to the parent swung from profit to loss. During the reporting period, it achieved operating revenue of 79.84 million yuan, down 20.42% year on year. Net profit attributable to the parent was negative 12.34 million yuan, swinging from profit to loss year on year. Net profit attributable to the parent after deducting non-recurring items was negative 18.51 million yuan, with the loss widening. Net cash flow from operating activities was 12.71 million yuan, down 27.34% year on year, but still remained a net inflow. The decline in performance mainly stemmed from three factors. Industry pressure led to a reduction in operating revenue of approximately 20.49 million yuan. Credit impairment losses increased by 4.21 million yuan year on year. The subsidiary Yuanqi Biotech recognized goodwill impairment of 3.51 million yuan, combined with the parent company writing off deferred tax assets of 5.46 million yuan. Despite the overall revenue decline, the number of hospital admissions for core products continued to grow. Important products added 58 new hospital admissions, including 30 for leukemia products and 17 for lymphoma products. High-end quantitative testing products such as BCR-ABL P210 won bids at multiple top-tier hospitals. In addition, the company's research and development investment decreased by 38.74% year on year, mainly due to adjustments in research and development strategy and staff streamlining.
Shanghai Rightongene Biotechnology Co. Ltd. A2026 interim report shows revenue down 20.42% and net profit swinging to a loss of 12.34 million yuan.
Subsidiary Yuanqi Biotech recognized a goodwill impairment of 3.51 million yuan, contributing to the parent's loss.
